Advertisement


Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

2025 ASCO Annual Meeting

Advertisement

Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I want to welcome everybody to the 2025 ASCO Annual Meeting. This is, as always, an exciting time in the year for us, when so much new science gets presented. Today, what I’m really excited about—above and beyond the cutting-edge new knowledge that’s being shared at this meeting—is how we’re going to distribute it to maximize impact for patients everywhere. The growth in information is something that we’re all grappling with. The explosion in publications—papers, that is—and information that could truly benefit patients is, I think, well known. The question is: how do we keep up? Even within ASCO, where we generate trusted, vetted, expert-prepared, peer-reviewed guidelines, it can be a problem just to find the information that a busy clinician needs in their day to make sure they are offering their patients the most up-to-date care possible. So thinking about those two related issues—the exploding basis of knowledge and the challenge of navigating to quick, accurate answers that a clinician can trust—the last year for us at ASCO has been an exciting one. We’ve partnered and collaborated with Google Cloud to create the ASCO Guidelines Assistant. And it is exactly what the name says—it’s really a discovery tool. What’s different about it compared to some other chat experiences that members may have had is that its answers to our questions are limited to the content of our guidelines. For every answer it gives, it automatically provides the relevant citation. If a user clicks on it, it shows them the specific guideline, when it was last updated, and it highlights in yellow the specific text within the guideline that supports the statement. So it addresses the question of trust, it addresses the question of discoverability, and it addresses the question of timeliness. We are really excited to be able to offer that to all of our members simply by logging on to the ASCO member app or going directly to the website at asco.org. GA—the name standing for Guidelines Assistant—is a small but really important step, I think, in our continuing journey to bring optimal, high-quality care to patients everywhere.

Related Videos

Prostate Cancer

Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?

Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004). 

Breast Cancer

Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award

Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.

Breast Cancer

Stephen K.L. Chia, MD, FRCPC, on Advanced HER2-Negative and ER-Positive Breast Cancer: SERD and AKT Inhibitor

Stephen K.L. Chia, MD, FRCPC, of BC Cancer Agency, reviews data from the phase III CCTG/BCT MA.40/FINER trial of fulvestrant and ipatasertib for advanced HER2-negative, ER-positive breast cancer following disease progression on first-line CDK 4/6 and aromatase inhibitors (LBA1005). 

Prostate Cancer
AI in Oncology

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001). 

 

Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program 

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screening for individuals with Li-Fraumeni syndrome (Abstract 10501). 

Advertisement

Advertisement




Advertisement